<![CDATA[Emerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLC ]]>
Few molecular subtypes in thoracic oncology have undergone as dramatic a therapeutic transformation in recent years as EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), according to Zosia Piotrowska, MD, MHS. Once considered " …